Cleary Gottlieb Steen & Hamilton (Washington)

Kenneth Reinker

Cleary Gottlieb Steen & Hamilton (Washington)
Partner

Kenneth’s practice spans all industries, including extensive experience with pharmaceuticals, medical devices, and healthcare; high-technology industries; media; and financial institutions. He has particular experience in antitrust economics and, after law school and prior to joining the firm, worked as an antitrust economist on monopolization litigation as executive director of Legal Economics LLC. Kenneth joined the firm in 2010 and became a partner in 2016.

Distinctions

Linked authors

Cleary Gottlieb Steen & Hamilton (Cologne)
Cleary Gottlieb Steen & Hamilton (London)
Cleary Gottlieb Steen & Hamilton (Hong Kong)
Cleary Gottlieb Steen & Hamilton (Brussels)
Cleary Gottlieb Steen & Hamilton (Brussels)

Articles

976 Bulletin

Leah Brannon, Jeremy J. Calsyn, George S. Cary, Daniel P. Culley, Elaine Ewing, David I. Gelfand, Bruce Hoffman, Heather Nyong’o, Kenneth Reinker The US FTC and DoJ announce plans to review and update merger guidelines in order to strengthen enforcement against illegal mergers

230

On Tuesday, January 18th, FTC Chair Lina Khan and DOJ Antitrust Division Assistant Attorney General Jonathan Kanter held a joint press conference in which they announced ambitious plans to review and update the Merger Guidelines, targeting a release of new guidelines before the end of 2022. (...)

Bruce Hoffman, Kenneth Reinker The US Supreme Court holds that Section 13(b) of the FTC Act does not authorize the Federal Trade Commission to seek, or a court to award, equitable monetary relief such as restitution or disgorgement (AMG Capital Management)

196

On April 22, 2021, the Supreme Court unanimously held that section 13(b) of the Federal Trade Commission Act - which authorizes “a permanent injunction”- does not authorize the Federal Trade Commission to seek, or a court to award, equitable monetary relief such as restitution or disgorgement. (...)

Kenneth Reinker, Bruce Hoffman, Kathleen W. Bradish, George S. Cary The US Court of Appeals for the Fifth Circuit upholds the FTC’s decision in the first fully litigated reverse payment decision against generic pharmaceutical companies (Endo / Impax)

447

On April 13, the U.S. Court of Appeals for the Fifth Circuit affirmed the Federal Trade Commission’s decision that Impax Laboratories entered an anticompetitive “reverse payment” settlement with Endo Pharmaceuticals. This case was the FTC’s first fully litigated reverse payment case since the (...)

Leah Brannon, Brian Byrne, Jeremy J. Calsyn, George S. Cary, Alexis Collins, Daniel P. Culley, Elaine Ewing, David I. Gelfand, Bruce Hoffman, Mark W. Nelson, Kenneth Reinker The US FTC issues commentary on vertical merger enforcement explaining the approach to assessing the competitive effects of vertical mergers

91

On December 22, 2020, the US Federal Trade Commission (the “FTC”) issued a Commentary on Vertical Merger Enforcement. This follows the recent issuance of revised Vertical Merger Guidelines published jointly by the FTC and Department of Justice (the “Agencies”) on June 30, 2020. While the Guidelines (...)

Leah Brannon, Brian Byrne, Jeremy J. Calsyn, George S. Cary, Daniel P. Culley, Elaine Ewing, David I. Gelfand, Bruce Hoffman, Kenneth Reinker The US FTC and DoJ publish final revised vertical merger guidelines

12

On June 30, 2020, the US Department of Justice and Federal Trade Commission (the “Agencies”) published final Vertical Merger Guidelines. Draft Guidelines were previously released for public comment on January 10. The Guidelines largely reflect the Agencies’ current approach and do not appear to (...)

Send a message